Form 4: RxSight Director Granted 35,668 RSUs

RxSight, Inc. Director Raymond W. Cohen was granted 35,668 restricted stock units (RSUs) effective July 31, 2025.

Summary

• Raymond W. Cohen, a Director of RxSight, Inc. (RXST), was granted 35,668 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was July 31, 2025.
• Each RSU represents a contingent right to receive one share of RxSight, Inc. Common Stock.
• The RSUs were acquired at a price of $0 per unit, which is typical for equity grants.
• Following this transaction, Raymond W. Cohen beneficially owns 35,668 shares directly.
• One third of the granted RSUs will vest on each annual anniversary of July 31, 2025, contingent on Mr. Cohen's continued service as an Outside Director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of equity to a director aligns their interests with shareholders and is a standard practice for executive compensation, indicating commitment.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a common method to attract and retain experienced directors.

Negatives

• The future vesting of these RSUs will result in a slight dilution of existing shareholder equity, though this is a standard practice for equity compensation plans.

Risks

• The vesting of the granted RSUs is contingent upon Raymond W. Cohen's continued service as an Outside Director through the applicable vesting dates.

Future Outlook

The filing indicates a future vesting schedule for the granted RSUs, with one-third vesting annually from July 31, 2025, subject to the director's continued service.

Industry Context

Equity grants to directors are a standard practice across various industries, particularly in the medical technology and healthcare sectors, to incentivize long-term commitment and align leadership interests with company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as compensation for an outside director is a common practice in the U.S. public company landscape, aligning with typical corporate governance and compensation structures.
• The vesting schedule of one-third annually over three years is a standard approach for RSU grants, similar to those observed at comparable medical device companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon RSU vesting, but increased alignment of a director's interests with long-term company performance and shareholder value.
• Employees: No direct impact mentioned, but reflects the company's approach to equity-based compensation.

Next Steps

• One third of the 35,668 RSUs are scheduled to vest on each annual anniversary of July 31, 2025, contingent on the director's continued service.

Key Dates

Keywords

RxSight, RXST, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4